Related Experiment Video
Updated: Aug 31, 2026
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
Cancer vaccines: an old idea comes of age
Leisha A Emens1, Elizabeth M Jaffee
1Departments of Oncology, The Sidney Kimmel Comprehensive Cancer Center; Baltimore, Maryland 21231-1000, USA. emensle@jhmi.edu
Abstract:
Cancer vaccines are at the forefront of novel, targeted approaches to cancer treatment. Low toxicity, the potential for circumventing drug cross-resistance, and the potential for persistence of the antitumor effect due to immunologic memory represent a mandate for accelerated clinical development. Advances in molecular immunology have suggested approaches for overcoming the formidable mechanisms of immune tolerance that are pre-established in cancer patients, and many have already been tested in preclinical models. Also, early studies revealed that not all tumor antigens are created equal, and identifying those capable of eliciting immune-mediated tumor rejection is essential to the development of effective recombinant cancer vaccines. While early trials have generally resulted in disappointing clinical outcomes, they have yielded insight into the critical parameters for the design of cancer vaccine trials and provided powerful reagents for tumor antigen identification. By utilizing the lessons learned from the research laboratory and these early clinical trials, informative second generation vaccine trials should have a high likelihood of success. Clinical protocols that consider how best to incorporate therapeutic cancer vaccines into the current standard of care should allow cancer vaccines to take their place alongside traditional cancer treatment modalities in oncology practice.
Insights
Cancer vaccines offer a targeted treatment with low toxicity and potential for long-lasting effects. Lessons from early trials are guiding the development of more effective, next-generation cancer vaccines.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Cancer vaccines represent a novel, targeted therapeutic strategy with low toxicity and potential for durable antitumor effects via immunologic memory.
- Overcoming immune tolerance in cancer patients is crucial for vaccine efficacy, with many strategies explored in preclinical models.
- Identifying effective tumor antigens is essential for developing successful recombinant cancer vaccines.
Purpose of the Study:
- To review the progress and challenges in cancer vaccine development.
- To highlight the importance of tumor antigen identification for vaccine design.
- To outline the path forward for next-generation cancer vaccine trials.
Main Methods:
- Review of advances in molecular immunology and preclinical cancer vaccine models.
- Analysis of outcomes from early-phase clinical trials.
- Identification of critical parameters for cancer vaccine trial design.
Main Results:
- Early cancer vaccine trials, while yielding disappointing clinical outcomes, provided crucial insights into vaccine design and antigen identification.
- Not all tumor antigens are equally effective; selection is key for eliciting immune-mediated tumor rejection.
- Lessons learned are informing the design of more effective second-generation vaccine trials.
Conclusions:
- Next-generation cancer vaccine trials, informed by past research and early clinical data, are poised for greater success.
- Integrating therapeutic cancer vaccines into standard care protocols is essential for their widespread adoption in oncology practice.
- Cancer vaccines have the potential to become a significant addition to traditional cancer treatment modalities.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:59Cancer Prevention
Some...
02:59Cancer Prevention
Some...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...